*All times listed are Central European Time (CET)
7:20 am Morning Check-in, Coffee & Light Breakfast
8:20 am Chair’s Opening Remarks
Shaping Healthcare Policy & Regulations & Engaging Hospitals to Expand Access Across More Patients in Need
8:30 am Transforming the Lives of Patients Through Precision Radiopharmaceuticals: Patient & Health Care System Stories
Synopsis
- Learn about the positive impact radiopharmaceuticals are having on patient communities
- Hear from clinicians who have seen radiopharmaceuticals on boarded in hospitals and breaking down misconceptions
- Garner key insights to transform your clinical design and improve patient engagement
9:00 am Panel Discussion: Obstacles & Opportunities in the Pricing & Reimbursement of Radiopharmaceuticals Across European Countries – Comparing UK, France & Germany
9:30 am Outlining the EANM Guidance Document: Dosimetry for First-in-human Studies & Early Phase Clinical Trials
Synopsis
- Exploring different emitters and carrier molecules
- Outlining methods for activity measurement, pharmacokinetic analyses, as well as absorbed dose calculations and uncertainty analyses
- Discussing the optimal use of preclinical information and studies involving diagnostic analogues
10:00 am Speed Networking & Refreshments
Preclinical & Translational Track
Finetuning Dosing & Toxicity Considerations for Radiopharmaceuticals to Ensure Patient Safety
11:30 am Optimising Dosing in Translational Radiopharmaceutical Studies
Synopsis
- Using dosimetry to help determine dosing
- Optimising treatment regimens
- Preclinical screening and computational modelling
12:00 pm Innovation Spotlight
Synopsis
- Your chance to see the latest technologies being applied to preclinical radiopharmaceutical development
- Observe and get to know 3 innovative new solutions in this lightning-round technical demonstration
12:15 pm Exploring Affibody Molecules as Vehicles for Molecular Radiotherapy of HER2- expressing Malignancies: ABY-025 for Patient Selection & ABY-271 for Radioligand Therapy
Synopsis
- Selecting patients by immunohistochemistry has limitations and image-guided decisions have recently proven superior
- Using the PET tracer ABY-025 to demonstrate correlation with improved treatment response prediction and can be translated therapeutically using linker technology for improved kinetics
- ABY-271 is a candidate in late preclinical development for molecular radiotherapy of HER2 expressing cancers
Clinical & Supply Chain Track
Strengthening Your Radiopharmaceutical Production & Transport Expertise to Ensure no Trial Hold Up
11:30 am Streamlining Your Radiopharmaceuticals Logistics Chains to Deliver Quality Drug Product to Patients on Time
Synopsis
- Exploring drug product release and quality assurance
- Optimising transport, tracking and delivery to ensure your drug doesn’t get hold up
- Uncovering tracking methods to streamline with patient
12:00 pm Session Reserved For:
Synopsis
12:15 pm Panel Discussion: A Supply Chain Lens: Exploring Isotope Viability from Production Challenges to Market Potential
Synopsis
- Assessing various isotopes and their supply challenges from continuing lutetium supply to
- actinium and lead
- Market potential and competition across isotope development
- Solutions for newer companies in the field
1:00 pm
Preclinical & Translational Track
Supercharging the Field by Exploring Novel Radiopharmaceutical Targets
1:45 pm Uncovering Novel Radiopharmaceutical Targets DLL3
Synopsis
- Uncovering targeting potential
- Gaining preclinical insights
- Exploring treatment potential for tough to treat lung cancer
2:15 pm Radionuclide Therapy Improvement Using Radiosensitizers: Preclinical Studies & Future Outlook
Synopsis
- Showcasing various preclinical studies (in vitro and in vivo)
- Addressing different combination treatments of 177Lu-based radionuclide therapies and agents such as DNA damage repair inhibitors
- Discussing cellular mechanisms and how to use this knowledge to design future (clinical) combination studies
Clinical & Supply Chain Track
Expanding Combination Based Approaches to Maximise Clinical Efficacy of TRPs
1:45 pm Panel Discussion: Phase 0 for Radiopharmaceuticals: Benefits & Risks
Synopsis
- Uncovering the rationale behind conducting these preliminary studies
- Exploring the pharmacokinetic and pharmacodynamic data it can provide
- Considerations for initiating a phase 0 trial
2:15 pm Bringing Novel Targets to the Clinic
Synopsis
- Novel target selection to expand use in different solid tumors
- Vector selection: Small molecules or mAb or both?
- Sharing topline clinical imaging data
12:45 pm Lunch Break & Networking
2:45 pm Afternoon Break & Networking
Amplifying the Field: Spanning More Targets & Advancing Indications with Radiopharmaceuticals
3:15 pm Assessing Future Directions for Addressing Unmet Medical Need by Expanding Indications & Selecting Novel Targets
Synopsis
- Identifying existing targets to be adapted to radiopharmaceuticals
- Exploring areas of unmet need and market potential
- Uncovering market predictions
3:45 pm Illuminating Advances in Click – Cleavable Radioimmunotherapy Programme
Synopsis
- Increasing efficacy and decreasing toxicity with click chemistry
- Ensuring off-target deactivation of unwanted circulating radiopharmaceuticals